Loading…
MORPHINE SULFATE is a brand name for Morphine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For the relief of severe pain in adults, adolescents (aged 13-18 years and children (ages 1-12 years).
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults:
Recommended dose 10-20 mg (5 - 10ml) every 4 hours. 5 ml) every 4 hours Maximum daily dose: 30 mg per day Children under 1 year: Not recommended Dosage can be increased under medical supervision according to the severity of the pain and the patient's previous history of analgesic requirements.
3), renal impairment, severe hypothyroidism, adrenocortical insufficiency, prostatic hypertrophy, shock or where sedation is undesirable. Treatment goals and discontinuation Before initiating treatment with Morphine Sulfate Oral Solution, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines.
During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with Morphine Sulfate Oral Solution, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal.
4). Duration of treatment Morphine Sulfate Oral Solution should not be used longer than necessary. Method of Administration For oral use. When patients are transferred from other morphine preparations oral preparations dosage titration may be appropriate.
Morphine sulfate is readily absorbed from the gastro-intestinal tract following oral administration. However, when Morphine Sulfate Oral Solution is used in place of parenteral morphine, a 50 % to 100 % increase in dosage is usually required in order to achieve the same level of analgesia.
In normal doses, the commonest side effects of morphine sulfate are nausea, vomiting, constipation, drowsiness and confusion. If constipation occurs, this may be treated with appropriate laxatives. The effects of morphine have led to its abuse and misuse.
Dependence and addiction may develop with regular, inappropriate use. Data from clinical trials are not available. Therefore it is not possible to provide information on the frequencies of undesirable effects except where stated. 6) Hepatobiliary disorders Biliary colic Spasm of sphincter of Oddi Skin and subcutaneous tissue disorders Urticaria Pruritus Hyperhidrosis Acute generalised exanthematous pustulosis (AGEP) Musculoskeletal and connective tissue disorders Muscle rigidity Renal and urinary disorders Dysuria Ureteral spasm Oliguria Reproductive system and breast disorders Decreased libido Erectile dysfunction *Frequency uncommon (≥ 1/1,000 to < 1/100) Drug dependence Repeated use of Morphine Sulfate Oral Solution can lead to drug dependence, even at therapeutic doses.
4). Reporting of suspected adverse drug reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
2), • and where there is reduced respiratory function, such as kyphoscoliosis, emphysema, cor pulmonale and severe obesity. Asthma It has been suggested that opioids can be used with caution in controlled asthma. 3). 3). The capacity of morphine to elevate cerebrospinal fluid pressure may be greatly increased in the presence of already elevated intracranial pressure produced by trauma.
Also, morphine may produce confusion, miosis, vomiting and other adverse reactions which may obscure the clinical course of patients with head injury. 3), or if the patient has bowel or obstructive biliary disease. Should paralytic ileus be suspected or occurring during these, Morphine Sulfate Oral Solution should be discontinued immediately.
Caution should be exercised where there is an obstructive bowel disorder, biliary colic, operations on the biliary tract, acute pancreatitis or prostatic hyperplasia. If constipation occurs, this may be treated with the appropriate laxatives.
Care should be exercised in patients with inflammatory bowel disease. Morphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions and complications following abdominal surgery. 5). Opioid Use Disorder (abuse and dependence) Morphine sulfate is an opioid agonist and controlled drug.
Tolerance and physical and/or psychological dependence may develop upon repeated administration of opioids such as Morphine Sulfate Oral Solution. Repeated use of Morphine Sulfate Oral Solution can lead to Opioid Use Disorder (OUD).
A higher dose and longer duration of opioid treatment, can increase the risk of developing OUD. Abuse or intentional misuse of Morphine Sulfate Oral Solution may result in overdose and/or death. g. major depression, anxiety and personality disorders).
2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician. g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines).
5) • patients with phaeochromocytoma. 4 for information relating to use in controlled asthma)
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Morphine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered. A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on- line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers.
These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Morphine sulfate may be abused by inhaling or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death. Patients should be closely monitored for signs of misuse, abuse, or addiction.
The clinical need for analgesic treatment should be reviewed regularly. Drug withdrawal syndrome Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with Morphine Sulfate Oral Solution.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome. Hyperalgesia Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain.
This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse […]